Trial Profile
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Prezalumab (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors MedImmune
- 05 Sep 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Planned End Date changed from 27 Aug 2018 to 2 Aug 2018.
- 22 Nov 2017 Status changed from recruiting to active, no longer recruiting.